U.S. Hotel and Resort REITs Stock News

In recent days, investors have reacted to Adobe’s ongoing pivot toward AI-powered, freemium tools while reassessing its valuation against peers amid heightened execution risks. At the same time, competitor Figma’s heavier AI spending and profit pressure, alongside growing options-market uncertainty around Adobe, has sharpened focus on how AI investments could affect Adobe’s business model. Building on this, we’ll examine how Adobe’s AI-driven freemium shift and the execution risk it...

Tariff refunds running into the billions for companies like Apple, Amazon and Walmart are reshaping the legal and compliance battleground in Washington. That money may stay with companies, flow to consumers or trigger tough new rules, and each path creates different winners. This article walks through three U.S. Legal and Compliance Services stocks exposed to this tariff drama so you can evaluate which stories appear more promising or more risky for your own watchlist. The three stocks below...

CRISPR Therapeutics earnings spark fresh interest in the stock CRISPR Therapeutics (NasdaqGM:CRSP) is back in focus after reporting second quarter 2026 results on 3 August, with higher revenue of US$10.18 million and a reduced net loss of US$91.15 million. See our latest analysis for CRISPR Therapeutics. CRISPR Therapeutics’ latest earnings have arrived alongside a sharp 1 day share price return of 3.64% and a 7 day share price return of 11.52%. However, the 1 month share price return is down...

What IPG Photonics’ Latest Earnings Tell You IPG Photonics (IPGP) just reported second quarter 2026 results, giving you fresh data on how the laser systems specialist is performing. Sales and profits moved in different directions, which matters for how you assess the stock. The company reported second quarter sales of US$278.58 million compared with US$250.72 million a year earlier. Net income was US$5.24 million compared with US$6.61 million, and diluted earnings per share from continuing...

In the past few days, Neurocrine Biosciences reported second-quarter 2026 results showing revenue of US$959 million and net income of US$144.4 million, alongside a new US$742 million shelf registration for 4,000,000 common shares tied to an ESOP-related offering. The combination of higher earnings per share and additional equity capacity highlights how Neurocrine Biosciences is simultaneously reinforcing employee ownership and funding flexibility. Now we’ll consider how this stronger...

Zoetis came into this earnings print wearing a value label, trading on an 11.6x trailing P/E that sat well below large pharma peers. The stock then dropped almost 6% in a single session, wiping away any hint of calm around the animal health story. The reason sits squarely in profit pressure. Management cut full year guidance, now pointing to an adjusted diluted earnings per share range of US$6.15 to US$6.25 and organic adjusted net income that is expected to decline mid to high single...

Nutex Health stock jumped 6.7% in the first full trading day after earnings, a sharp move for a company many investors still file mentally under small cap and controversial reimbursement story. The headline is not revenue; the story is profit. Q2 net income reached US$65.8m on revenue of US$210.8m, and trailing net profit margin now sits at 21.2% with a P/E of 6.2x. The market is quickly repricing a business that screens as inexpensive and more profitable than its reputation suggests. Like...

Atlanticus Holdings just saw its stock drop about 11% in a single session, yet the latest quarter reads more like an earnings statement from a company on the front foot than one in retreat. The credit focused lender posted Q2 2026 revenue of US$223.6m and basic earnings per share of US$3.13, both tied to net income of US$47.4m. Investors came into this print after a strong three month run in the stock, which makes the sharp pullback a reset on expectations rather than a simple verdict on the...

Centrus Energy (LEU) just signed a definitive contract to supply X-energy with Low Enriched Uranium and High Assay Low Enriched Uranium, backed by customer prepayments that support Centrus Energy's domestic enrichment capacity build out. See our latest analysis for Centrus Energy. These new enrichment contracts arrive as Centrus Energy’s share price has moved sharply in the short term, with a 1-day share price return of 7.49% and a 30-day share price return of 14.96%. However, the year to...

Waters stock reacts to fresh guidance and earnings update Waters (WAT) has drawn investor attention after issuing new revenue guidance for the third quarter and full year 2026, alongside second quarter results that showed higher sales and a shift to a net loss. See our latest analysis for Waters. The recent guidance and earnings update come after a strong run in Waters stock. The 90 day share price return of 14.57% and the 1 year total shareholder return of 44.69% suggest that momentum has...

PennyMac Financial Services (PFSI) recently reported second quarter 2026 earnings that showed net income of US$22 million and basic earnings per share of US$0.42, compared with US$136 million and US$2.64 a year earlier. See our latest analysis for PennyMac Financial Services. The sharp fall in PennyMac Financial Services' second quarter earnings appears to have coincided with weaker share price momentum, with the stock down 41.14% on a year to date share price return, despite a 3 year total...

Recent momentum in AMC Entertainment Holdings stock Recent trading interest in AMC Entertainment Holdings (AMC) has picked up after the stock showed strong momentum in recent weeks, supported by upward earnings estimate revisions and a favorable third party ranking. See our latest analysis for AMC Entertainment Holdings. For context, AMC Entertainment Holdings has a recent 30-day share price return of 35.60% and a 90-day share price return of 72.67%, while the 1-year total shareholder return...

ON Semiconductor recently reported past second-quarter 2026 results, with sales of US$1,603.5 million and diluted EPS of US$0.56, and issued third-quarter guidance calling for US$1,650–US$1,750 million in revenue and diluted EPS of US$0.79–US$0.91. The company also continued returning cash to shareholders, completing a buyback of 8,847,540 shares for US$677.63 million, while year-to-date net income shifted from a prior-year loss to a profit. Next, we’ll examine how this combination of...

Annaly Capital Management stock has delivered a 73.6% return over the past three years, while the current intrinsic value estimate from the Excess Returns model and the earnings based multiples both point to the shares trading at a discount to assessed fair value. At the same time, Annaly scores a mixed result on the broader valuation checks, which keeps the debate open on how much of that discount is usable for investors. A 73.6% return over three years suggests Annaly Capital Management...

The market marked down MarketWise by just over 5% to US$20.25, yet the headline from Q2 is not a collapse in demand. The real story is a sharp squeeze in profitability. Revenue for the quarter sat around US$75.8m, while the company swung to a reported net loss. That pressure also shows up in the trailing net profit margin, which sits at 0.7%, well below where it was a year ago. Today’s price move looks like a fast verdict on that margin strain. It also raises a deeper question about how...

V.F (VFC) just packed several developments into two days. The company reported first quarter results, raised its fiscal 2027 revenue outlook, and named Abhishek Dalmia as Chief Financial Officer. See our latest analysis for V.F. The latest earnings report, higher fiscal 2027 revenue outlook, dividend affirmation and CFO appointment have come as V.F’s share price sits at US$14.99. Short term share price momentum is fading, with the 30 day return down 6.43% and the 90 day return down 21.02%,...

Himax Technologies just jumped 6.3% in a single session, a sharp move for a stock that had been down over the past three months. The market is latching onto one headline: earnings power snapping back in a big way. Basic earnings per share for the quarter came in at about US$0.23 on revenue of roughly US$227.4m, a clear step up from recent prints in this display chipmaker’s cycle. With the stock already trading on a rich trailing P/E of about 72x, the key question now is whether this earnings...

In the past quarter, Trulieve Cannabis Corp. reported second-quarter 2026 sales of US$271 million, down from US$302.1 million a year earlier, with net loss widening to US$406 million and basic and diluted loss per share from continuing operations at US$2.10, compared with US$0.07 previously. Over the first half of 2026, sales softened to US$557.7 million from US$599.8 million while net loss expanded to US$403.6 million and loss per share from continuing operations rose to US$2.09,...

Manitowoc Company just shocked a skeptical market. The stock rose 32.4% to US$18.82 after traders digested a quarter that flipped from a Q1 loss to Q2 basic earnings per share of about US$0.39 and pushed net income to US$14.2m. For a crane maker often viewed as a low margin grinder, the main focus is margin repair. Adjusted EBITDA nearly doubled to US$49m with margin above 8%, helped by stronger crane demand and a meaningful tariff refund tailwind. Love the sharp margin repair at Manitowoc...

In the past week, Figma, Inc. reported second-quarter 2026 results with revenue rising to US$370.08 million from US$249.64 million a year earlier, while swinging from a US$28.23 million net profit to a US$112.15 million net loss and issuing higher full-year 2026 revenue guidance of about US$1.46 billion. The quarter marked Figma’s first full period of AI credit monetization, revealing that new AI features are expanding customer usage even as heavier AI infrastructure spending sharply...

Precision BioSciences stock barely flinched after earnings, edging only 0.9% higher to US$7.49. Yet the quarter itself was anything but quiet. The headline is a sharp swing back into loss making territory, with Q2 basic earnings per share at a loss of US$1.26 and revenue dropping to essentially zero. For a biotech that investors often value on future potential, the real story today is the strain this kind of income statement puts on the balance between patience and dilution risk. The price...

Exponent, Inc. recently reported past second-quarter 2026 results showing year-on-year growth in sales to US$148.86 million, revenue to US$171.61 million, and net income to US$29.4 million, alongside confirming a US$0.31 per-share dividend and completing a multi-year share repurchase of 13,868,342 shares. The company also raised its 2026 revenue growth guidance, signaled further quarterly net revenue growth for the second half of the year, and expanded its equity buyback authorization by...

With the U.S. economy shedding 23,000 jobs in July and inflation holding above 3.5%, reliable dividend growth can feel more valuable than ever. Paychecks are under pressure, yet some companies continue to raise payouts at a measured pace. This article walks through three dividend growth stocks that appear better placed to handle this softer labor backdrop so you can judge whether they deserve a closer look now. The stocks covered below are a useful sample of dividend growth ideas, yet the...

In the past quarter, Western Midstream Partners, LP reported second-quarter 2026 revenue of US$1,224.72 million and net income of US$394.88 million, with basic and diluted EPS from continuing operations of US$0.99, alongside modest impairment charges of US$551,000 and sequential increases in throughput across natural gas, crude oil, NGLs, and produced water. The partnership also affirmed a second-quarter 2026 cash distribution of US$0.930 per unit on an annualized US$3.72 basis and filed a...